2026年1月8日，深圳市精锋医疗科技股份有限公司（股票代码：02675.HK）以"精锋医疗-B"之名正式在香 港联交所主板挂牌上市。此次IPO发行价每股43.24港元，开盘大涨36.45%报59港元，市值突破200亿港元。 至此，这家由两位海归博士王建辰与高元倩在 2017年创立的手术机器人企业，正式挺进了全球高端医疗科技 竞争的核心战场。 其公开发售获近 1092倍认购的火爆场景背后，是包括阿布扎比投资局（ADIA）、瑞银、腾讯、OrbiMed等 13家顶级基石投资者的鼎力支持，合计认购7500万美元。其中，中东最大主权基金之一的ADIA豪掷1500万 美元，成为最大基石投资者。这不仅是一次资本盛宴，更是国产手术机器人完成技术破局后，迈向全球市场的 一个关键信号。 ▍ 硬核技术立身：全栈自研构筑双重护城河 精锋医疗由麻省理工学院博士王建辰与哈佛大学博士高元倩于 2017年联合创立。二人均师从中国机器人专家 王树新教授，在手术机器人领域深耕近十年。 创业之初，国内手术机器人赛道尚处萌芽，达芬奇在国内装机量不足百台。但未被满足的庞大临床需求与技术 自主的产业抱负，驱动了这家公司的诞生。 创业之初，最大的共识与 ...

Core Viewpoint - Singapore's Temasek-backed surgical robotics company, Precision Medicine, has secretly applied for an IPO in Hong Kong, aiming to raise approximately $150 million to $200 million, with details still to be confirmed [1] Company Overview - Precision Medicine was founded in 2017 by two PhD graduates from MIT and Harvard, Wang Jianchen and Gao Yuanqian [1] - The company is the first in China and the second globally to offer products for multi-port, single-port, and bronchoscopic surgical robots [1] Financial Information - The company completed a crossover financing round in December 2021, achieving a valuation exceeding $1.5 billion (approximately 10.6 billion RMB) [1] Product Details - Core products include: - Multi-port laparoscopic surgical robot MP1000 - Single-port laparoscopic surgical robot SP1000 - Natural orifice surgical robot CP1000 - The MP1000 completed its clinical trial for urological surgery in December 2021 and submitted its registration application to the National Medical Products Administration (NMPA) in January 2022 [1] - The clinical trial was led by a renowned academician, demonstrating excellent efficacy and safety [1] - As of August 2023, the MP1000 has been approved for use across all departments [1]

Core Viewpoint - Singapore's Temasek-backed surgical robotics company, Precision Medicine, has secretly applied for a Hong Kong IPO, aiming to raise approximately $150 million to $200 million, with details on the IPO scale and timing still to be determined [1] Company Overview - Precision Medicine was founded in 2017 by two PhD graduates from MIT and Harvard, Wang Jianchen and Gao Yuanqian, and is the first in China and the second globally to offer multi-port, single-port, and bronchoscopic surgical robot products [1] - The company achieved a valuation exceeding $1.5 billion (approximately 10.6 billion RMB) after completing a crossover financing round in December 2021 [1] Product Information - The core products of Precision Medicine include: - Multi-port laparoscopic surgical robot MP1000 - Single-port laparoscopic surgical robot SP1000 - Natural orifice transluminal endoscopic surgery (NOTES) robot CP1000 - The MP1000 completed its registration clinical trial for urological surgery in December 2021 and submitted its registration application to the National Medical Products Administration (NMPA) in January 2022, led by a renowned academician, demonstrating excellent efficacy and safety [1] - As of August 2023, the MP1000 has been approved for use in all departments [1]